NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
| NCT ID | NCT05867420 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | AskGene Pharma, Inc. |
| Condition | Advanced Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 594 participants |
| Start Date | 2023-08-02 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 594 participants in total. It began in 2023-08-02 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Histologically or cytologically confirmed advanced malignant tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available. 2. ECOG performance status of ≤ 2. 3. Life expectancy of ≥ 3 months. 4. The results of the laboratory tests must meet all criteria. Exclusion Criteria: 1. Patients have received antitumor therapy during the first 4 weeks before study drug use. 2. Received a live attenuated vaccine within 4 weeks prior to C1D1. 3. Known cerebral parenchymal metastasis or meningeal metastasis. 4. History of serious cardiovascular or cerebrovascular diseases. 5. Active or recurrent autoimmune diseases. 6. History of ascites or pleural effusion requiring drainage. 7. Pregnant or lactating or planning to become pregnant at any time during the study, including the Follow-up Period.
Contact & Investigator
Jing Chen, MD
STUDY DIRECTOR
Ask-Gene Pharma, Inc.
Frequently Asked Questions
Who can join the NCT05867420 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05867420 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05867420 currently recruiting?
Yes, NCT05867420 is actively recruiting participants. Contact the research team at chenjing@ask-pharm.com for enrollment information.
Where is the NCT05867420 trial being conducted?
This trial is being conducted at New York, United States, Pittsburgh, United States, Beijing, China, Shanghai, China.
Who is sponsoring the NCT05867420 clinical trial?
NCT05867420 is sponsored by AskGene Pharma, Inc.. The principal investigator is Jing Chen, MD at Ask-Gene Pharma, Inc.. The trial plans to enroll 594 participants.